We Offer Worldwide Shipping
Login Wishlist

Irinotecan Hydrochloride

$144

  • Brand : BIOFRON

  • Catalogue Number : BD-D1190

  • Specification : HPLC≥98%

  • CAS number : 97682-44-5

  • Formula : C33H38N4O6

  • Molecular Weight : 586.68

  • PUBCHEM ID : 60838

  • Volume : 20mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-D1190

Analysis Method

Specification

HPLC≥98%

Storage

-20℃

Molecular Weight

586.68

Appearance

Powder

Botanical Source

Structure Type

Category

SMILES

CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)OC(=O)N6CCC(CC6)N7CCCCC7

Synonyms

Irinotecan/7-ethoxyxanthone-3-carboxylic acid/Campto/(+)-Irinotecan/9H-Xanthene-3-carboxylic acid,7-ethoxy-9-oxo/(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 1,4'-bipiperidine-1'-carboxylate/[1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester

IUPAC Name

Density

1.4±0.1 g/cm3

Solubility

Flash Point

482.0±34.3 °C

Boiling Point

873.4±65.0 °C at 760 mmHg

Melting Point

InChl

InChl Key

UWKQSNNFCGGAFS-XIFFEERXSA-N

WGK Germany

RID/ADR

HS Code Reference

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:97682-44-5) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

31670091

Abstract

The drug edaravone (EDA) is prescribed for the treatment of patients with amyotrophic lateral sclerosis or after an acute cerebral infarction. This synthetic pyrazolone derivative is a potent scavenger of oxygen free radicals and also functions as a modulator of transcription factors, repressing NFκB and activating Nrf2, to regulate oxidative stress. EDA displays complementary anti-oxidative and anti-inflammatory effects. The injectable small molecule is currently investigated for the treatment of several non-neurological diseases. The potential interest of EDA in oncology is reviewed here. EDA is a mild antiproliferative agent but has been found to enhance significantly the anticancer and antimetastatic activities of irinotecan in a colon cancer model. Anticancer derivatives of EDA have been designed but they generally display a limited antiproliferative activity. The antioxidant and anti-inflammatory activity of EDA can be best exploited to protect non-tumor cells from damages induced by chemotherapeutic drugs and radiations. Notably EDA can reduce the renal dysfunction induced by cisplatin, the neurotoxicity of cyclophosphamide and the cardiotoxicity of doxorubicin. Upon treatment with EDA, a significant improvement in neurologic symptoms has been observed in patients with nasopharyngeal carcinoma after radiotherapy. The drug could be used to limit radiation-induced brain injury or oral mucositis. EDA was found to ameliorate autoimmune thyroiditis (Hashimoto thyroiditis), which is a frequent side effect observed after treatment of cancer patients with monoclonal antibodies targeting the immune checkpoint PD-1. Therefore, EDA could also be useful to reduce specific side effects of immuno-therapy. Collectively, the information suggests that the medical use of EDA, a drug with a proven safety after 18 years of use in brain-related Human diseases, could be extended to cancer-related conditions.

Copyright © 2019 Elsevier B.V. All rights reserved

KEYWORDS

ALS; Cancer; Chemotherapy; Cisplatin (PubChem CID: 441203); Edaravone; Edaravone (PubChem CID: 89-25-8); Immunotherapy; Inflammation; Irinotecan (PubChem CID: 97682-44-5); Masitinib (PubChem CID: 790299-79-5); Oxygen radicals; Radiotherapy; Riluzole (PubChem CID: 1744-22-5)

Title

Potential use of edaravone to reduce specific side effects of chemo-, radio- and immuno-therapy of cancers.

Author

Bailly C1.

Publish date

2019 Dec;

PMID

29999936

Title

Irinotecan.

PMID

19634513

Abstract

Allometry has been extensively used in the modern day drug development scenario to predict the human relevant parameters (clearance, Cl, and volume of distribution at steady state, Vss) from animal data. The applicability of allometry in the prediction of human parameters for irinotecan (CAS 97682-44-5), an important topoisomerase I inhibitor, has been retrospectively investigated. Literature pharmacokinetic data has been gathered for both irinotecan and its main metabolite, SN-38 (CAS 86639-52-3), from several animal species. The corresponding human parameters were predicted using allometry (Cl and Vss for irinotecan; Cl/F for SN-38). Although irinotecan has a complex metabolism and disposition profile, it appeared that simple allometry predicted satisfactorily the human values for Cl (1.7648W(0.669)) and Vss (3.1277W(0.9044)) for irinotecan. On the contrary, Cl/F for SN-38 was over predicted by simple allometry (53.389W(1.2773)); and the applicability of bile correction factor rendered Cl/F of SN-38 to be closer to the observed human value (8.9641W(1.3108)). The investigation suggests that prospective allometric approaches may aid in the development of future compounds in this important pharmacological and chemical class of cytotoxics.

Title

Allometric scaling of a metabolically complex camptothecin analog: differences in scaling of irinotecan and its active metabolite, SN-38.

Author

Ahlawat P1, Srinivas NR.

Publish date

2009;


Description :

Empty ...